Black Cohosh for Menopause: Cautious Yes, Cautious No
Black cohosh (Actaea racemosa) is the most popular herbal supplement for menopausal hot flushes in the West, but the evidence sits on the fence. A Cochrane review of 16 trials in over 2,000 women found no consistent effect on hot-flush frequency or intensity — some trials helped, others did nothing — and the 2023 North American Menopause Society no longer recommends it. The bigger issue is rare but real liver injury: case reports tie it to acute hepatitis, so regulators now require liver-warning labels, even though controlled trials have not shown raised liver enzymes. It is a reasonable short-term try (a standardized 40–80 mg/day extract, reviewed at 6 months) for mild symptoms in women without liver risk factors who cannot use hormone therapy, but it should be avoided in pregnancy and used cautiously by breast-cancer survivors.
The hot flash evidence
A Cochrane review of 16 placebo-controlled trials (n=2,027) found no consistent benefit on the frequency or intensity of hot flushes — some trials showed modest improvement, others showed none, and pooling did not produce a robust effect (Leach 2012; PMID 22786509; DOI 10.1002/14651858.CD007244.pub2). The 2023 North American Menopause Society non-hormone therapy position statement does not recommend black cohosh for vasomotor symptoms, citing inconsistent efficacy and safety concerns (NAMS 2023). The German standardised iCR/Remifemin extract has the most consistent individual-trial record but doesn't reliably outperform placebo in pooled analyses.
Not phytoestrogenic
Unlike soy isoflavones or red clover, black cohosh does not bind oestrogen receptors. The mechanism is unclear and likely involves serotonergic and dopaminergic effects. That spares it the theoretical endometrial-stimulation risk of phytoestrogens, but it also means it doesn't reliably address oestrogen-dependent symptoms like vaginal atrophy or bone loss.
The hepatotoxicity question
Since the late 1990s, multiple post-marketing case reports have linked black cohosh products to acute hepatitis, with a small number progressing to transplantation. A structured causality reanalysis of 69 reported cases concluded that confounders (concomitant medication, comorbid liver disease, product mislabelling) made a definitive causal link difficult, with only a minority meeting probable or highly probable causality (Teschke 2009; PMID 19010650). RCT-level data have not shown elevated liver enzyme rates. The EU regulator's position is that idiosyncratic hepatotoxicity is rare but plausible, and labels must warn users to discontinue with any signs of liver injury (fatigue, dark urine, jaundice, pale stools).
Safety and dose
Typical dose is 20–40 mg twice daily of standardised iCR/Remifemin extract or equivalent (40–80 mg total). Evidence is strongest for use up to 6 months. Avoid in pregnancy and breastfeeding (insufficient data), and use with caution in breast-cancer survivors. Avoid combination with other hepatotoxic medications and consider checking liver enzymes at baseline and during use. Stop 2 weeks before elective surgery.
Where it fits
A reasonable option for mild-to-moderate vasomotor symptoms in people who cannot or prefer not to use HRT, SSRIs/SNRIs, or gabapentin, and who don't have liver risk factors. A 6-month review point is sensible: if symptoms aren't materially better, stop.
Sources
- Leach MJ, Moore V. "Black cohosh (Cimicifuga spp.) for menopausal symptoms." Cochrane Database of Systematic Reviews, 2012;(9):CD007244. PMID 22786509; DOI 10.1002/14651858.CD007244.pub2.
- Teschke R, Schwarzenboeck A. "Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment." Phytomedicine, 2009;16(1):72–84. PMID 19010650.
- The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Advisory Panel. "The 2023 nonhormone therapy position statement of The North American Menopause Society." Menopause, 2023;30(6):573–590.